Study on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Systemic Lupus Erythematosus

2 1

What is this study about?

This clinical trial is focused on studying the long-term safety and effectiveness of a medication called deucravacitinib, also known by its code name BMS-986165. The study is specifically for individuals with Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease where the immune system attacks the body’s own tissues, causing inflammation and damage to various organs.

The purpose of the study is to understand how safe and tolerable deucravacitinib is for people with SLE over an extended period. Participants in the study will receive either a 3 mg, 6 mg, or 12 mg dose of deucravacitinib in the form of a film-coated tablet, or a placebo, which looks like the medication but does not contain the active ingredient. The medication is taken orally, meaning it is swallowed. The study will monitor participants for any side effects and assess how well the medication works in managing the symptoms of SLE.

Throughout the study, participants will have regular check-ups to track their health and any changes in their condition. The study aims to provide valuable information on the long-term use of deucravacitinib for treating Systemic Lupus Erythematosus, helping to determine its potential as a treatment option for this condition.

1 joining the study

Upon joining the study, the participant must have completed a previous study and be currently receiving a study drug. In certain cases, exceptions may be made for those not currently receiving the drug due to specific circumstances.

Women of childbearing potential must undergo a pregnancy test before starting the study drug and agree to use contraception during the study and for a specified period after the last dose.

2 medication administration

The study involves the administration of deucravacitinib, which is taken orally in the form of film-coated tablets.

The available dosages are 3 mg, 6 mg, and 12 mg tablets. A placebo tablet may also be used to match the appearance of the deucravacitinib tablets.

3 monitoring and assessments

Throughout the study, participants will be monitored for any adverse events or serious adverse events. Vital signs and laboratory parameters will be regularly checked.

The study will also assess the efficacy of the treatment through various measures, including joint counts, skin assessments, and other clinical responses.

4 end of study

The study is expected to conclude by March 31, 2025. Participants will continue to be monitored until the end of the study period.

After the study, participants will be evaluated for any long-term effects of the treatment.

Who Can Join the Study?

The patient must have signed a written informed consent form, which means they agree to participate in the study after being informed about it.
The patient must have completed a previous study called IM011021 and be currently receiving a study drug that is not identified to them (blinded study drug). If the patient missed the study drug due to special situations like the COVID-19 pandemic, they might still join with approval from the study doctor.
For women who can have children, they must have a negative pregnancy test before starting the study drug. This test checks for a hormone called human chorionic gonadotropin (hCG) to ensure they are not pregnant.
Women must not be pregnant, breastfeeding, or planning to become pregnant during the study.
Women who can have children must agree to use effective birth control methods while taking the study drug and for a total of 33 days after the last dose. This is to prevent pregnancy during and shortly after the study.
Women who are not sexually active with men do not need to use birth control but still need to take pregnancy tests as required by the study.
Men who are sexually active with women who can have children must agree to use birth control methods during the study.
Men who cannot produce sperm (azoospermic) do not need to use birth control.

Who Cannot Join the Study?

Having any other serious health condition that could interfere with the study.
Being pregnant or planning to become pregnant during the study.
Currently breastfeeding.
Having a history of severe allergic reactions to medications.
Using certain medications that might interfere with the study treatment.
Having a recent history of drug or alcohol abuse.
Participating in another clinical trial at the same time.
Having an active infection that requires treatment.
Having a history of certain types of cancer.
Having a weakened immune system.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
CENTRUM MEDYCZNE REUMA PARK	Warsaw	Poland

Other Sites

Site Name	City	Country
Synexus Polska Sp. z o.o.	Wroclaw	Poland
Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy	Bydgoszcz	Poland
Hospital Universitario Virgen De Valme	Sevilla	Spain
Medyczne Centrum Hetmanska	Poznan	Poland
Mtz Clinical Research Powered By Pratia	Warsaw	Poland
Bekes Varmegyei Koezponti Korhaz	Gyula	Hungary
Centrum Medyczne Plejady Magdalena Celinska Loewenhoff Michal Zolnowski sp.k.	Cracow	Poland
Reumed Sp. z o.o.	Lublin	Poland
Centrum Medyczne Oporow	Wroclaw	Poland
Spitalul Clinic Judetean De Urgenta Sf. Apostol Andrei Galati	Galati	Romania
Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o.	Cracow	Poland
University Of Szeged	Szeged	Hungary
Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne Promimed Sp. z o.o. sp.k.	Cracow	Poland
Pdqc Tpcsq Hgygvlsg Untoswvkdzlk	Sabadell	Spain
Shlkdrca Jtracidk dt Ujjncrg Vedvmf	Ramnicu Valcea	Romania
cmqxrou mayiutxq Mtdftq sqrt Ggssjiz pwmqadmp lisbblyp	Sosnowiec	Poland
Ikifmgaonue	Kościan	Poland
Cfvbjqo Mhwrcyr Df Dgkmfddnug Sr Tcwmaxrmv Amyymzvwx Njcats Sbmadz	Brasov	Romania

Trial status

Country	Status	Recruitment Start
Hungary	Not recruiting	19.06.2019
Poland	Not recruiting	19.06.2019
Romania	Not recruiting	19.06.2019
Spain	Not recruiting	19.06.2019

Trial locations

Investigated drugs:

Deucravacitinib

BMS-986165 is a medication being studied for its long-term safety and effectiveness in people with systemic lupus erythematosus (SLE). This medication is being tested to see how well it can be tolerated by patients over an extended period and to understand its potential benefits in managing the symptoms of SLE.

Systemic Lupus Erythematosus – Systemic Lupus Erythematosus (SLE) is an autoimmune disease where the immune system mistakenly attacks healthy tissues in the body. It can affect various parts of the body, including the skin, joints, kidneys, brain, and other organs. The disease often presents with symptoms such as fatigue, joint pain, skin rashes, and fever. SLE is characterized by periods of illness, called flares, and periods of wellness, or remission. The severity and symptoms of the disease can vary widely among individuals. Over time, SLE can lead to damage in the affected organs and tissues.

Trial ID:

2022-502444-13-00

Protocol code:

IM011074

NCT ID:

NCT03920267

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Systemic Lupus Erythematosus

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?